Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-hydroxy-5-(2-mercapto-ethylsulfamoyl)-benzoic acid is a synthetic small molecule belonging to the benzenesulfonamide class of organic compounds. It contains a sulfonamide group attached to a hydroxybenzoic acid core, with an additional mercaptoethyl substituent. The compound has been cataloged in chemical and pharmaceutical databases as an experimental agent, but there are no approved medical indications or clinical trial data available for therapeutic use. Its mechanism of action is not well characterized, though it has been listed as having potential interaction with caspase proteins in some datasets[1][2]. No evidence supports its use as an approved drug or investigational therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-hydroxy-5-(2-mercapto-ethylsulfamoyl)-benzoic acid.